{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:29:32Z","timestamp":1773318572021,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007166","name":"Jiangsu Provincial Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570257"],"award-info":[{"award-number":["82570257"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neo.2025.101242","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:33:43Z","timestamp":1761316423000},"page":"101242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting Wnt\/\u03b2-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma"],"prefix":"10.1016","volume":"70","author":[{"given":"Heng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Gregorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-5109","authenticated-orcid":false,"given":"Marcel","family":"Spaargaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven T.","family":"Pals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0691-8789","authenticated-orcid":false,"given":"Zemin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101242_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/OP-24-00752","article-title":"Novel treatment options for multiple myeloma","author":"Portuguese","year":"2025","journal-title":"JCo Oncol. Pract."},{"issue":"15","key":"10.1016\/j.neo.2025.101242_bib0002","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.2024025897","article-title":"Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS","volume":"145","author":"Landgren","year":"2025","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.neo.2025.101242_bib0003","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.2024027932","article-title":"Daratumumab: a game changer in early myeloma","volume":"145","author":"Mateos","year":"2025","journal-title":"Blood"},{"issue":"10272","key":"10.1016\/j.neo.2025.101242_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 Daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neo.2025.101242_bib0006","doi-asserted-by":"crossref","unstructured":"Z Ren, H van Andel, W de Lau, et al. Syndecan-1 promotes Wnt\/\u03b2-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood. Mar 1 2018;131(9):982-994, doi:10.1182\/blood-2017-07-797050.","DOI":"10.1182\/blood-2017-07-797050"},{"issue":"2","key":"10.1016\/j.neo.2025.101242_bib0007","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1073\/pnas.1618650114","article-title":"Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins","volume":"114","author":"van Andel","year":"2017","journal-title":"Proc Natl Acad Sci U S A. Jan 10"},{"issue":"12","key":"10.1016\/j.neo.2025.101242_bib0008","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/sj.leu.2404939","article-title":"Epigenetic dysregulation of wnt signaling pathway in multiple myeloma","volume":"21","author":"Chim","year":"2007","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.neo.2025.101242_bib0009","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2008-12-194290","article-title":"Aurora kinase A is a target of wnt\/beta-catenin involved in multiple myeloma disease progression","volume":"114","author":"Dutta-Simmons","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.neo.2025.101242_bib0010","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.neo.2025.101242_bib0011","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/1078-0432.CCR-08-1350","article-title":"beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model","volume":"15","author":"Ashihara","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.neo.2025.101242_bib0012","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"Sukhdeo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.neo.2025.101242_bib0013","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-16-0624","article-title":"\u03b2-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma","volume":"16","author":"Savvidou","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7397","key":"10.1016\/j.neo.2025.101242_bib0014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nature11019","article-title":"ZNRF3 promotes wnt receptor turnover in an R-spondin-sensitive manner","volume":"485","author":"Hao","year":"2012","journal-title":"Nature"},{"issue":"7706","key":"10.1016\/j.neo.2025.101242_bib0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41586-018-0118-y","article-title":"RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4\/5\/6","volume":"557","author":"Szenker-Ravi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101242_bib0016","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev-biochem-040320-103615","article-title":"The Wnt pathway: from signaling mechanisms to synthetic modulators","volume":"91","author":"Rim","year":"2022","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.neo.2025.101242_bib0017","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.neo.2025.101242_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.neo.2025.101242_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060941","article-title":"Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.neo.2025.101242_bib0021","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2003-06-2151","article-title":"Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis","volume":"103","author":"Bharti","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.neo.2025.101242_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046892","article-title":"The Wnt\/\u03b2-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells","volume":"7","author":"Fragoso","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neo.2025.101242_bib0024","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s10120-021-01186-5","article-title":"Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric. Cancer"},{"issue":"11","key":"10.1016\/j.neo.2025.101242_bib0025","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist."},{"issue":"6","key":"10.1016\/j.neo.2025.101242_bib0026","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.neo.2025.101242_bib0027","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.neo.2025.101242_bib0028","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","author":"Garc\u00eda-Guerrero","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.neo.2025.101242_bib0030","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","article-title":"Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma","volume":"14","author":"Ziccheddu","year":"2024","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.neo.2025.101242_bib0032","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2025.101242_bib0033","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.neo.2025.101242_bib0034","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.neo.2025.101242_bib0035","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.neo.2025.101242_bib0036","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.neo.2025.101242_bib0037","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.neo.2025.101242_bib0038","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/stem.1752","article-title":"STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer","volume":"32","author":"Wei","year":"2014","journal-title":"Stem Cells."},{"issue":"2","key":"10.1016\/j.neo.2025.101242_bib0039","doi-asserted-by":"crossref","first-page":"e9370","DOI":"10.1371\/journal.pone.0009370","article-title":"Lentiviral vectors to probe and manipulate the Wnt signaling pathway","volume":"5","author":"Fuerer","year":"2010","journal-title":"PLoS. One"},{"issue":"34","key":"10.1016\/j.neo.2025.101242_bib0040","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1073\/pnas.0404875101","article-title":"A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]","volume":"101","author":"Emami","year":"2004","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.neo.2025.101242_bib0041","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-210469","article-title":"Activating STAT3 mutations drive CD38 expression in T-large granular lymphocytic leukemia","volume":"144","author":"Calabretto","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.neo.2025.101242_bib0042","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.neo.2025.101242_bib0043","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood.2024028107","article-title":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","volume":"146","author":"Diamond","year":"2025","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.neo.2025.101242_bib0044","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1182\/bloodadvances.2023011295","article-title":"Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma","volume":"7","author":"Portuguese","year":"2023","journal-title":"Blood Adv."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:45:34Z","timestamp":1773254734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"alternative-id":["S1476558625001228"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101242","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Wnt\/\u03b2-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101242"}}